Titan Pharma (TTNP) Announces Receipt of FDA Approval for Probuphine as Opioid Dependence Treatment
Tweet Send to a Friend
Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) announced that the U.S. Food and Drug Administration has approved Probuphine (buprenorphine) implant, the first ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
